Intellia Therapeutics (NASDAQ:NTLA) Stock Falls 8.3% – Here’s Why

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s share price dropped 8.3% on Tuesday. The company traded as low as $11.08 and last traded at $11.11. 1,127,780 shares changed hands during trading, a decline of 78% from the average session volume of 5,103,586 shares. The stock had previously closed at $12.11.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $25 price target, signaling continued confidence despite lowering its earnings forecasts.
• Neutral Sentiment: Intellia reported inducement grants under Nasdaq listing rules; the provided report does not specify their size or likely financial impact. Intellia Therapeutics reports inducement grants
• Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS estimates, including its FY2026 forecast to a loss of $3.24 per share from $3.06 and its FY2027 forecast to a loss of $3.17 from $3.12. It also reduced estimates for several 2027 quarters.
• Negative Sentiment: Brookline Capital Markets cut its FY2026 estimate to a loss of $2.92 per share and lowered its longer-term profit forecasts for 2029 and 2030, tempering expectations for future earnings growth.
• Negative Sentiment: The company’s latest reported quarter also missed analyst expectations for both EPS and revenue; revenue fell 47.8% year over year. These results add to the concerns reflected in the forecast cuts.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NTLA. Wedbush lifted their target price on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 9th. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. Barclays started coverage on Intellia Therapeutics in a report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price target on the stock. Evercore upgraded Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target on the stock in a research note on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $21.44.

Intellia Therapeutics Price Performance

The company has a 50-day moving average of $12.08 and a two-hundred day moving average of $13.04. The company has a market capitalization of $1.57 billion, a PE ratio of -3.34 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $9.74 million. During the same quarter in the previous year, the company earned ($0.92) EPS. The business’s quarterly revenue was down 47.8% compared to the same quarter last year. As a group, research analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 EPS for the current year.

Insider Buying and Selling at Intellia Therapeutics

In related news, CEO John M. Leonard sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total transaction of $107,910.00. Following the completion of the transaction, the chief executive officer directly owned 1,138,064 shares in the company, valued at approximately $13,645,387.36. The trade was a 0.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. HighTower Advisors LLC raised its position in shares of Intellia Therapeutics by 107.6% during the 3rd quarter. HighTower Advisors LLC now owns 101,968 shares of the company’s stock valued at $1,230,000 after purchasing an additional 52,839 shares during the period. Wellington Grp LLC lifted its stake in shares of Intellia Therapeutics by 65.3% during the 3rd quarter. Wellington Grp LLC now owns 111,876 shares of the company’s stock valued at $1,349,000 after buying an additional 44,188 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Intellia Therapeutics by 64.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 210,990 shares of the company’s stock valued at $2,545,000 after buying an additional 82,737 shares in the last quarter. Gen Wealth Partners Inc boosted its holdings in Intellia Therapeutics by 34.0% in the 3rd quarter. Gen Wealth Partners Inc now owns 82,177 shares of the company’s stock worth $991,000 after buying an additional 20,834 shares during the period. Finally, Fulcrum Asset Management LLP bought a new position in Intellia Therapeutics in the 3rd quarter worth $165,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.